|
|
||||||||
1 Division of Cardiovascular Surgery, Department of Surgery, 2 Nicotine Research Center, Department of Internal Medicine, 3 Department of Laboratory Medicine, 4 Department of Physiology and Biophysics, 5 Division of Endocrinology, Department of Internal Medicine, and 6 Section of Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota 55905
Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.
endothelium; nitric oxide; saphenous vein; smoking cessation; vascular smooth muscle
This article has been cited by other articles:
![]() |
D. Xiao, X. Huang, J. Lawrence, S. Yang, and L. Zhang Fetal and Neonatal Nicotine Exposure Differentially Regulates Vascular Contractility in Adult Male and Female Offspring J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 654 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rzewuska-Lech, M. Jayachandran, L. A. Fitzpatrick, and V. M. Miller Differential effects of 17{beta}-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E105 - E112. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Ambrose and R. S. Barua The pathophysiology of cigarette smoking and cardiovascular disease: An update J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1731 - 1737. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Moyer, J. R. Charlson, R. J. Enger, L. C. Dale, J. O. Ebbert, D. R. Schroeder, and R. D. Hurt Simultaneous Analysis of Nicotine, Nicotine Metabolites, and Tobacco Alkaloids in Serum or Urine by Tandem Mass Spectrometry, with Clinically Relevant Metabolic Profiles Clin. Chem., September 1, 2002; 48(9): 1460 - 1471. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Miller, W. D. Clouse, B. H. Tonnessen, U. S. Boston, S. R. Severson, S. Bonde, K. S. Rud, and R. D. Hurt Time and dose effect of transdermal nicotine on endothelial function Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1913 - H1921. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |